2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment

Keyphrases

• Clinical Practice Guidelines 100%
• Eradication Therapy 100%
• Helicobacter Pylori Eradication 100%
• Pharmacological Treatment 50%
• Bismuth Quadruple Therapy 50%
• Helicobacter Pylori Infection 50%
• China 25%
• Control Disease 25%
• Developing Countries 25%
• Prevalence Rate 25%
• Resource Use 25%
• Developed Countries 25%
• Healthcare 25%
• Bismuth 25%
• Disease Progression 25%
• Antibiotic Resistance 25%
• Low-middle Income Countries 25%
• Infectious Diseases 25%
• World Health Organization 25%
• Reporting Item 25%
• Evaluation Assessment 25%
• Assessment Development 25%
• Public Health Burden 25%
• Grading of Recommendations 25%
• Clinical Practice Guideline Development 25%
• Guidelines International Network 25%
• Gastric Cancer 25%
• Resource-limited Settings 25%
• Helicobacter Pylori (H. pylori) 25%
• Stakeholder Preferences 25%
• Clinical Recommendations 25%
• Antibiotic Resistance Pattern 25%
• Evidence to Decision Framework 25%
• Minimizing Bias 25%
• Indigestion 25%
• Peptic Ulcer 25%
• Stakeholder Value 25%
• Gastritis 25%
• Rescue Treatment 25%
• Practice Guidelines 25%
• Initial Treatment 25%
• High-dose Dual Therapy 25%

Medicine and Dentistry

• Helicobacter Pylori 100%
• Prevalence 40%
• Drug Therapy 40%
• Helicobacter Infection 40%
• Antibiotic Resistance 40%
• Gastritis 20%
• Infection 20%
• Public Health 20%
• Drug Megadose 20%
• Disease Exacerbation 20%
• Low and Middle Income Countries 20%
• Emergency Medical Technician 20%
• Stomach Cancer 20%
• Jejunum Ulcer 20%
• Empirical Treatment 20%
• Dyspepsia 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Helicobacter Pylori 100%
• Prevalence 40%
• Antibiotic Resistance 40%
• Helicobacter Infection 40%
• Infection 20%
• Stomach Cancer 20%
• Disease Exacerbation 20%
• Indigestion 20%
• Gastritis 20%
• Jejunum Ulcer 20%